Factors associated with efficacy of FOLFIRI/aflibercept in patients with metastatic colon cancer
M. Yu. Fedyanin,
L. Yu. Vladimirova,
V. A. Chubenko,
L. A. Zagorskaya,
A. V. Belyaeva,
L. V. Bolotina,
F. V. Moiseenko,
O. L. Fakhrutdinova,
S. A. Belukhin,
A. S. Zhabina,
L. V. Khalikova,
V. M. Moiseenko,
А. А. Meshcheryakov,
E. V. Artamonova,
I. A. Pokataev,
A. I. Khasanova,
A. V. Belonogov,
Kh. S. Musaeva,
O. Yu. Novikova,
I. Yu. Stradaeva,
I. L. Popova,
G. Z. Mukhametshina,
R. V. Orlova,
S. P. Erdniev,
A. K. Ivanova,
A. V. Androsova,
P. S. Feoktistova,
E. S. Kuzmina,
E. V. Karabina,
O. V. Nekrasova,
V. M. Sherstnev,
A. A. Mishchenko,
L. A. Mukova,
B. Kh. Kertiev,
G. I. Kosar,
S. N. Osodoeva,
A. I. Kats,
R. R. Malina,
A. A. Tryakin,
S. A. Tjulandin https://doi.org/10.17650/2220-3478-2019-9-2-29-37
Abstract
Objective: to identify factors associated with efficacy of an aflibercept-chemotherapy combination in patients with metastatic colon cancer.
Materials and methods. This retrospective multicenter study was conducted in 20 clinics from 15 regions of the Russian Federation. The main efficacy outcome was progression-free survival (PFS). We performed univariate and multivariate analysis to assess the impact of various factors of PFS.
Results. Two hundred and fifty-seven patients received aflibercept-containing chemotherapy; of them, 175 participants (68.1 %) received it as a second-line therapy. The objective response rate and median PFS were 18.7% and 5 months (95% confidence interval (CI) 4.2—5.8) respec -tively. The following factors were found to have a positive effect of PFS at multivariate analysis: grade I—II adverse events to aflibercept therapy (hazard ratio (HR) 0.58; 95 % CI 0.38—0.89; p = 0.01), therapy for concomitant diseases (HR 0.47; 95 % CI 0.29—0.76; p = 0.002), and ECOG performance status of 0 (HR 0.53; 95 % CI 0.34—0.81; p = 0.004). Patient with all 3 factors present had median PFS of 9 months, whereas patients without them demonstrated PFS of only 3 months (HR 1.9; 95 % CI 1.5—2.6; p <0.001).
Conclusions. Satisfactory performance status, adequate therapy for concomitant diseases, and adverse events to aflibercept therapy were associated with better PFS in patients receiving aflibercept-containing chemotherapy.
About the Authors
M. Yu. Fedyanin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
L. Yu. Vladimirova
Rostov Research Institute of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
63 14th Line St., Rostov-on-Don 344037
V. A. Chubenko
Saint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of Russia
Russian Federation
Russian Federation
68A Leningradskaya St., Pesochny Settlement, Saint Petersburg 197758
L. A. Zagorskaya
Saint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of Russia
Russian Federation
Russian Federation
68A Leningradskaya St., Pesochny Settlement, Saint Petersburg 197758
A. V. Belyaeva
Saint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of Russia
Russian Federation
Russian Federation
68A Leningradskaya St., Pesochny Settlement, Saint Petersburg 197758
L. V. Bolotina
P.A. Hertzen Moscow Oncology Research Institute — branch of the National Medical Research Radiology Center, Ministry of Health of Russia
Russian Federation
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284
F. V. Moiseenko
Saint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of Russia
Russian Federation
Russian Federation
68A Leningradskaya St., Pesochny Settlement, Saint Petersburg 197758
O. L. Fakhrutdinova
Saint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of Russia
Russian Federation
Russian Federation
68A Leningradskaya St., Pesochny Settlement, Saint Petersburg 197758
S. A. Belukhin
Saint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of Russia
Russian Federation
Russian Federation
68A Leningradskaya St., Pesochny Settlement, Saint Petersburg 197758
A. S. Zhabina
Saint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of Russia
Russian Federation
Russian Federation
68A Leningradskaya St., Pesochny Settlement, Saint Petersburg 197758
L. V. Khalikova
Saint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of Russia
Russian Federation
Russian Federation
68A Leningradskaya St., Pesochny Settlement, Saint Petersburg 197758
V. M. Moiseenko
Saint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of Russia
Russian Federation
Russian Federation
68A Leningradskaya St., Pesochny Settlement, Saint Petersburg 197758
А. А. Meshcheryakov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
E. V. Artamonova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
I. A. Pokataev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
A. I. Khasanova
Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Tatarstan
Russian Federation
Russian Federation
29 Sibirskiy Road, Kazan 420029
A. V. Belonogov
MEDSIClinic
Russian Federation
16 Krasnaya Presnya St., Moscow 123242
Russian Federation
16 Krasnaya Presnya St., Moscow 123242
Kh. S. Musaeva
Republican Oncology Dispensary
Russian Federation
Russian Federation
81 Leonova St., Grozny 364029
O. Yu. Novikova
Regional Clinical Center of Oncology
Russian Federation
Russian Federation
164 Voronezhskoe Shosse, Khabarovsk 680042
I. Yu. Stradaeva
Moscow Regional Oncology Dispensary
Russian Federation
Russian Federation
6 Karbysheva St., Balashikha 143900
I. L. Popova
Rostov Research Institute of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
63 14th Line St., Rostov-on-Don 344037
G. Z. Mukhametshina
Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Tatarstan
Russian Federation
Russian Federation
29 Sibirskiy Road, Kazan 420029
R. V. Orlova
Saint Petersburg State University
Russian Federation
Russian Federation
Medical Faculty.
7—9 Universitetskaya Naberezhnaya, Saint Petersburg 199034
S. P. Erdniev
City Clinical Oncology Dispensary
Russian Federation
Russian Federation
3/5 2nd Berezovaya Alleya, Saint Petersburg 197022
A. K. Ivanova
City Clinical Oncology Dispensary
Russian Federation
Russian Federation
3/5 2nd Berezovaya Alleya, Saint Petersburg 197022
A. V. Androsova
City Clinical Oncology Dispensary
Russian Federation
Russian Federation
3/5 2nd Berezovaya Alleya, Saint Petersburg 197022
P. S. Feoktistova
Nizhnevartovsk Oncology Dispensary
Russian Federation
Russian Federation
9a Sportivnaya St., Nizhnevartovsk 628615
E. S. Kuzmina
Salekhard Regional Clinical Hospital
Russian Federation
Russian Federation
39 Mira St., Salekhard 629001
E. V. Karabina
Tula Regional Oncology Dispensary
Russian Federation
Russian Federation
201 Plekhanova St., Tula 300053
O. V. Nekrasova
Multicare Medical Center “Medical City”
Russian Federation
Russian Federation
32 Barnaulskaya St., Tyumen 625041
V. M. Sherstnev
Oncology Dispensary No. 5, Moscow Healthcare Department
Russian Federation
Russian Federation
5/1 Perervinskiy Bulvar, Moscow 109451
A. A. Mishchenko
Primorsky Regional Oncology Dispensary
Russian Federation
Russian Federation
59 Russkaya St., Vladivostok 690105
L. A. Mukova
Oncology Dispensary, Ministry of Health of Kabardino-Balkar Republic
Russian Federation
Russian Federation
23 Lermontova St., Nalchik 360051
B. Kh. Kertiev
Oncology Dispensary, Ministry of Health of Kabardino-Balkar Republic
Russian Federation
Russian Federation
23 Lermontova St., Nalchik 360051
G. I. Kosar
Volgodonsk Oncology Dispensary
Russian Federation
Russian Federation
46/45Pervomayskiy Per., Volgodonsk 347360
S. N. Osodoeva
Buryat Republican Oncology Dispensary
Russian Federation
Russian Federation
32 Pirogova St., Ulan-Ude 670047
A. I. Kats
Oncology Dispensary
Russian Federation
Russian Federation
23 Sholom-Aleykhema St., Birobidzhan 679016
R. R. Malina
Oncology Dispensary
Russian Federation
Russian Federation
23 Sholom-Aleykhema St., Birobidzhan 679016
A. A. Tryakin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
S. A. Tjulandin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
References
1. Van Cutsem E., Tabemero J., Lakomy R. et al. Addition of aflibercept to fluoroura-cil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499—506. DOI: 10.1200/JCO.2012.42.8201.
2. Vladimirova L., Fedyanin M., Chubenko V. et al. Aflibercept (Afl) for patients (pts) with metastatic colorectal cancer (mCRC): clinical predictors of nonhematologic (nonhem) toxicity. ASCO 2019. Abs. e15007.
3. Chau I., Joulain F., Iqbal S.U., Bridgewater J. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. BMC Cancer 2014;14:605. DOI: 10.1186/1471-2407-14-605.
4. Hurwitz H.I., Douglas P.S., Middleton J.P. et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 2013;18(3):273—80. DOI: 10.1634/theon-cologist.2012-0339.
5. Kohne C.H., Cunningham D., Di Costan-zo F. et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13:308-17.
6. Fedyanin M.Yu., Trya-kin A.A., Pokataev I.A., Tjulandin S.A. Meta-analysis of studies analyzing concordance of mutational status in matched primary and metastatic colon cancer. Onkol-ogicheskaya koloproktologiya = Colorectal Oncology 2017;7(1):27—41. (In Russ.).
7. Sims T.N., Gao B., Phillips R. et al. Potential predictive and prognostic biomarkers identified in baseline plasma samples from the VELOUR trial. J Clin Oncol 2015;3(suppl):638.
Review
Views:
800
Email this article 